AVICENNA RESEARCH Trademark

Trademark Overview


On Wednesday, July 26, 2023, a trademark application was filed for AVICENNA RESEARCH with the United States Patent and Trademark Office. The USPTO has given the AVICENNA RESEARCH trademark a serial number of 98102260. The federal status of this trademark filing is SUSPENSION LETTER - MAILED as of Friday, October 31, 2025. This trademark is owned by Avicenna Research Inc.. The AVICENNA RESEARCH trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Application service provider featuring application programming interface (API) software for analyzing molecular and clinical data for scientific and medical research; hosting an online community website for registered users to participate in discussions in the field of clinical trials and medical research; providing information on clinical studies via an interactive website; Software as a service (SaaS) services featuring software for clinical trial management; software as a service (SaaS) services featuring software for operating, managing, and administering clinical trials, recruiting patients, managing and monitoring data, capturing events, and reporting data; software as a service (SaaS) services featuring software for providing telemedicine services to patients; software as a service (SaaS) services featuring software for providing virtual healthcare services and healthcare consultations to patients; software as a service (SaaS) services featuring software for providing access to ...
avicenna research

General Information


Serial Number98102260
Word MarkAVICENNA RESEARCH
Filing DateWednesday, July 26, 2023
Status653 - SUSPENSION LETTER - MAILED
Status DateFriday, October 31, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesApplication service provider featuring application programming interface (API) software for analyzing molecular and clinical data for scientific and medical research; hosting an online community website for registered users to participate in discussions in the field of clinical trials and medical research; providing information on clinical studies via an interactive website; Software as a service (SaaS) services featuring software for clinical trial management; software as a service (SaaS) services featuring software for operating, managing, and administering clinical trials, recruiting patients, managing and monitoring data, capturing events, and reporting data; software as a service (SaaS) services featuring software for providing telemedicine services to patients; software as a service (SaaS) services featuring software for providing virtual healthcare services and healthcare consultations to patients; software as a service (SaaS) services featuring software for providing access to information on pharmaceuticals, clinical trials, and medical research; software as a service (SaaS) services featuring software for providing physician education, for accessing a healthcare application support tool used in providing delivery of medical treatments, and for accessing clinical decision support tools; software as a service (SaaS) services featuring software for patient engagement in clinical trials and when providing healthcare services; Creating an online community for registered users to participate in discussions, get feedback, form virtual communities, and engage in social networking in the field of clinical trials and medical research; Scientific research consulting services in the field of clinical trials, including design, planning, implementation, and project management of remote clinical trials utilizing mobile software applications; Application Service Provider (ASP) featuring software for hosting, managing, developing, analyzing, and maintaining applications, software, and websites in the fields of healthcare and healthcare research
NOT AVAILABLE"RESEARCH"

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, August 24, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAvicenna Research Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNorth York, Ontario M4N1T6
CA

Trademark Events


Event DateEvent Description
Saturday, July 29, 2023NEW APPLICATION ENTERED
Thursday, August 24, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, March 28, 2024ASSIGNED TO EXAMINER
Wednesday, May 8, 2024NON-FINAL ACTION WRITTEN
Wednesday, May 8, 2024NON-FINAL ACTION E-MAILED
Wednesday, May 8, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, August 8, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, August 8, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, August 8, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, August 8, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, August 8, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, August 12, 2024SUSPENSION LETTER WRITTEN
Monday, August 12, 2024LETTER OF SUSPENSION E-MAILED
Monday, August 12, 2024NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, February 10, 2025REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Monday, August 11, 2025SUSPENSION INQUIRY WRITTEN
Monday, August 11, 2025INQUIRY TO SUSPENSION E-MAILED
Monday, August 11, 2025NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Monday, October 6, 2025TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Wednesday, October 15, 2025ASSIGNED TO LIE
Wednesday, October 15, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, October 15, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, October 31, 2025SUSPENSION LETTER WRITTEN
Friday, October 31, 2025LETTER OF SUSPENSION E-MAILED
Friday, October 31, 2025NOTIFICATION OF LETTER OF SUSPENSION E-MAILED